查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542897

全球皮肤和软组织感染市场 - 2024-2031

Global Skin and Soft Tissue Infections Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

2023年，全球皮肤和软组织感染市场达到112.8371亿美元，预计到2031年将达到217.0855亿美元，2024-2031年预测期间复合年增长率为8.8%。

皮肤和软组织感染 (SSTI) 是皮肤、肌肉和结缔组织（如韧带和肌腱）的感染。 SSTI 最常见的原因是细菌，细菌可以透过各种开口进入人体，例如烧伤、微小割伤、擦伤和手术部位的伤口。

常见的单纯性SSTI包括蜂窝性组织炎、丹毒、脓疱疮、臁疮、毛囊炎、疖、痈、脓疡和创伤相关感染。复杂感染包括深部脓疡、褥疮、坏死性筋膜炎、福尼尔坏疽、人类或动物咬伤引起的感染。

市场动态：

驱动程式和限制

产品开发和批准不断增加

用于治疗皮肤和软组织感染的药物的不断开发和批准预计将推动市场成长。随着新药的开发，将为感染者提供多种产品。这增加了对新治疗产品的需求。

具有广泛应用的产品批准不断增加预计将增加对这些药物的需求。例如，2024年4月，美国食品药物管理局批准Zevtera（注射头孢比普罗美多卡利钠）用于治疗成人金黄色葡萄球菌血流感染（菌血症）（SAB），包括右侧感染性心内膜炎、成人急性细菌性皮肤及皮肤结构感染（ABSSSI）。

此外，2021年7月23日，艾伯维获得美国食品药物管理局（FDA）批准的DALVANCE（达巴万星）用于治疗出生后儿科患者的急性细菌性皮肤和皮肤结构感染（ABSSSI） 。 DALVANCE 是第一个以30 分钟静脉(IV) 输注形式给药的单剂量选择，用于治疗儿科患者由指定敏感革兰氏阳性菌引起的ABSSSI，包括由耐甲氧西林金黄色葡萄球菌( MRSA) 引起的感染。因此，上述因素可能会推动市场成长。

对新的传染性细菌菌株的抵抗力

耐万古霉素肠球菌（VRE）和抗甲氧西林金黄色葡萄球菌（MRSA）等抗生素抗药性细菌的出现，为SSTI的治疗带来了主要障碍。这降低了传统抗生素的有效性，导致治疗时间延长、医疗费用更高以及患者预后较差。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 产品开发和批准不断增加
    • 限制
      • 对新的传染性细菌菌株的抵抗力
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 报销分析
  • 专利分析
  • SWOT分析
  • DMI 意见

第 6 章：按类型

  • 感染性溃疡
  • 伤口感染
  • 脓肿
  • 蜂窝性组织炎
  • 外耳炎
  • 其他的

第 7 章：按药物类型

  • 抗生素
  • 抗真菌剂
  • 其他的

第 8 章：依给药途径分类

  • 专题
  • 口服
  • 注射用

第 9 章：按配销通路

  • 医院药房
  • 零售药局
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • GSK Plc
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Pfizer Inc.
  • Merck KGaA
  • Wellona Pharma
  • GL Pharma
  • Basilea Pharmaceutica AG
  • Invision Medi Sciences Pvt. Ltd.
  • Intelicure Lifesciences.
  • Steris Healthcare Pvt Ltd
  • SNU Biocare (*LIST NOT EXHAUSTIVE)

第 13 章：附录

简介目录
Product Code: PH33

Market Overview

The Global Skin and Soft Tissue Infections Market reached US$ 11,283.71 million in 2023 and is expected to reach US$ 21,708.55 million by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031.

Skin and Soft Tissue Infections (SSTI) are infections of the skin, muscles, and connective tissue such as ligaments and tendons. The most frequent cause of SSTIs is bacteria, which can enter the body through a variety of openings such as burns, tiny cuts, scrapes, and wounds from surgical sites.

Common simple SSTIs include cellulitis, erysipelas, impetigo, ecthyma, folliculitis, furuncles, carbuncles, abscesses, and trauma-related infections. Complicated infections include deep abscesses, decubitus ulcers, necrotizing fasciitis, Fournier gangrene, and infections from human or animal bites.

Market Dynamics: Drivers & Restraints

Rising product development and approvals

The rising developments and approvals of the drugs for the treatment of Skin and Soft Tissue Infections is expected to drive the market growth. With the development of new drugs there will be a wide range of products available for the individuals with the infections. This rises the demand for the new products for the treatment.

The rising product approvals with broad spectrum applications is expected to increase the demand for the drugs. For instance, in April 2024, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, adults with acute bacterial skin and skin structure infections (ABSSSI).

Additionally, July 23, 2021, AbbVie received the U.S. Food and Drug Administration (FDA) approved DALVANCE (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. DALVANCE is the first single-dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Thus, the above factors could drive the market growth.

Resistance to the new strains of infectious bacteria

The emergence of antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), presents a major obstacle to the treatment of SSTIs. This reduces the effectiveness of conventional antibiotics, leading to extended therapy times, higher medical expenses, and worse patient outcomes.

Segment Analysis

The global Skin and Soft Tissue Infections market is segmented based on type, drug type, route of Administration, distribution channel and region.

Antibiotics segment is expected to dominate the market share

Antibiotics segment holds a major position in the market share. For bacterial SSTIs, antibiotics are currently the primary form of treatment. They function well against a variety of bacterial pathogens, including Streptococcus pyogenes and Staphylococcus aureus, that can lead to skin infections. Antibiotics specifically target bacterial infections, that are a common cause of SSTIs.

The large number of prescriptions for and treatments for bacterial infections has created an significant position for antibiotics.

The market position of antibiotics is further built by ongoing research and development activities in antibiotic therapy, which lead to the creation of novel formulations, combinations, and enhanced efficacy against antibiotic-resistant bacteria. Thus, the above factors are expected to drive the segment growth.

Geographical Analysis

North America is expected to hold a significant position in the skin and soft tissue infections market share

North America is holding a dominant position in the market share owing to the increasing incidence of several Skin and Soft Tissue Infections in the region. The presence of a large number of pharmaceutical companies in the region is also expected to be a factor in the growth of the region's market.

The region has an advanced healthcare infrastructure with established hospitals and clinics. The hospitals and clinics have well-established diagnostic tools and the region also has well-established medical research and advancements in treatment options.

The increasing number of Skin and Soft Tissue Infections in the region increases demand for the new drugs that are developed in the region. For instance, according to the report by NIH in 2023, it is estimated that cellulitis is a very common skin infection that accounts for more than 14 million cases in the United States per year.

Additionally, according to the Agency for Healthcare Research and Quality, each year, more than 2.5 million people in the United States develop pressure ulcers. These skin lesions bring pain, associated risk for serious infection, and increased health care utilization. Pressure ulcers are associated with longer hospital stays and increased morbidity and mortality. Thus, the above factors are expected to hold the region in the dominant position.

Market Segmentation

By Type

Infected Ulcers

Wound Infections

Abscesses

Cellulitis

Otitis Externa

Others

By Drug Type

Antibiotics

Anti-fungal Agents

Others

By Route of Administration

Topical

Oral

Parenteral

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Competitive Landscape

The major global players in the market include GSK Plc, Pfizer Inc., Merck KGaA, Wellona Pharma, GL Pharma, Basilea Pharmaceutica AG, Invision Medi Sciences Pvt. Ltd., Intelicure Lifesciences., Steris Healthcare Pvt Ltd and SNU Biocare among others.

Why Purchase the Report?

To visualize the global skin and soft tissue infections market segmentation based on type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of skin and soft tissue infections market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global skin and soft tissue infections market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising product development and approvals
    • 4.1.2. Restraints
      • 4.1.2.1. Resistance to the new strains of infectious bacteria
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Infected Ulcers*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Wound Infections
  • 6.4. Abscesses
  • 6.5. Cellulitis
  • 6.6. Otitis Externa
  • 6.7. Others

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Antibiotics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Anti-fungal Agents
  • 7.4. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Topical*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Oral
  • 8.4. Parenteral

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. UK
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. GSK Plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Pfizer Inc.
  • 12.3. Merck KGaA
  • 12.4. Wellona Pharma
  • 12.5. GL Pharma
  • 12.6. Basilea Pharmaceutica AG
  • 12.7. Invision Medi Sciences Pvt. Ltd.
  • 12.8. Intelicure Lifesciences.
  • 12.9. Steris Healthcare Pvt Ltd
  • 12.10. SNU Biocare (*LIST NOT EXHAUSTIVE)

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us